The transcription factor oestrogen receptor alpha (ERα) has long been targeted for therapeutic benefit in cancer, but drug resistance can emerge through a multitude of mechanisms. A study now reveals how the ERα cistrome can become reprogrammed to confer resistance to tamoxifen in breast cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Darnell, J. E. Jr. Nat. Rev. Cancer 2, 740–749 (2002).
Bhagwat, A. S. & Vakoc, C. R. Trends Cancer 1, 53–65 (2015).
Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Cancer Cell 37, 496–513 (2020).
Bi, M. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-020-0514-z (2020).
Ross-Innes, C. S. et al. Nature 481, 389–393 (2012).
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. Nat. Genet. 43, 27–33 (2011).
Fu, X. et al. Proc. Natl. Acad. Sci. USA 113, E6600–E6609 (2016).
Malorni, L. et al. Mol. Cancer Res. 14, 470–481 (2016).
Lupien, M. et al. Genes Dev. 24, 2219–2227 (2010).
Hiscox, S. et al. Int. J. Cancer 118, 290–301 (2006).
Jakacka, M. et al. J. Biol. Chem. 276, 13615–13621 (2001).
Chen, D. et al. Mol. Cell 6, 127–137 (2000).
Jeselsohn, R. et al. Cancer Cell 33, 173–186.e5 (2018).
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L. & Chandarlapaty, S. Nat. Rev. Cancer 18, 662 (2018).
Guan, J. et al. Cell 178, 949–963.e18 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.R.V. has received funding from Boehringer Ingelheim and Syros Pharmaceuticals and is an advisor to KSQ Therapeutics.
Rights and permissions
About this article
Cite this article
Wu, X.S., Vakoc, C.R. A pliable ERα cistrome evades therapy. Nat Cell Biol 22, 619–620 (2020). https://doi.org/10.1038/s41556-020-0528-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-020-0528-6
- Springer Nature Limited